Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.

van Kempen LC, van den Hurk K, Lazar V, Michiels S, Winnepenninckx V, Stas M, Spatz A, van den Oord JJ.

Virchows Arch. 2012 Oct;461(4):441-8. doi: 10.1007/s00428-012-1309-9. Epub 2012 Sep 6.

PMID:
22956368
2.

Loss of microRNA-205 expression is associated with melanoma progression.

Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X.

Lab Invest. 2012 Jul;92(7):1084-96. doi: 10.1038/labinvest.2012.62. Epub 2012 Apr 23.

3.

Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.

Xu Y, Brenn T, Brown ER, Doherty V, Melton DW.

Br J Cancer. 2012 Jan 31;106(3):553-61. doi: 10.1038/bjc.2011.568. Epub 2012 Jan 5.

4.

miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

Liu S, Tetzlaff MT, Cui R, Xu X.

Am J Pathol. 2012 Nov;181(5):1823-35. doi: 10.1016/j.ajpath.2012.07.009. Epub 2012 Sep 13.

5.

Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.

Krengel S, Grotelüschen F, Bartsch S, Tronnier M.

J Cutan Pathol. 2004 Jan;31(1):1-7.

PMID:
14675278
6.

Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.

Bauer R, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK.

J Clin Pathol. 2006 Jul;59(7):699-705. Epub 2006 Mar 24.

7.

Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.

Bachmann IM, Ladstein RG, Straume O, Naumov GN, Akslen LA.

BMC Cancer. 2008 Dec 5;8:362. doi: 10.1186/1471-2407-8-362.

8.

Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.

Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH.

Oncogene. 2012 Feb 9;31(6):764-75. doi: 10.1038/onc.2011.269. Epub 2011 Jul 4.

PMID:
21725366
9.

MicroRNA miR-125b induces senescence in human melanoma cells.

Glud M, Manfé V, Biskup E, Holst L, Dirksen AM, Hastrup N, Nielsen FC, Drzewiecki KT, Gniadecki R.

Melanoma Res. 2011 Jun;21(3):253-6. doi: 10.1097/CMR.0b013e328345333b.

PMID:
21460750
10.

Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.

Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S.

Cancer. 2005 Apr 15;103(8):1693-700.

11.

Patterns of melastatin mRNA expression in melanocytic tumors.

Deeds J, Cronin F, Duncan LM.

Hum Pathol. 2000 Nov;31(11):1346-56.

PMID:
11112208
12.

Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.

Nazarian RM, Prieto VG, Elder DE, Duncan LM.

J Cutan Pathol. 2010 Apr;37 Suppl 1:41-7. doi: 10.1111/j.1600-0560.2010.01505.x.

PMID:
20482674
13.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer..

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
14.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

15.

miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells.

Dynoodt P, Speeckaert R, De Wever O, Chevolet I, Brochez L, Lambert J, Van Gele M.

Int J Oncol. 2013 Apr;42(4):1443-51. doi: 10.3892/ijo.2013.1823. Epub 2013 Feb 12.

PMID:
23404256
16.

Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.

Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J.

Mol Pathol. 1999 Jun;52(3):151-7.

17.

Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.

Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14.

18.

microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells.

Satzger I, Mattern A, Kuettler U, Weinspach D, Niebuhr M, Kapp A, Gutzmer R.

Exp Dermatol. 2012 Jul;21(7):509-14. doi: 10.1111/j.1600-0625.2012.01510.x.

PMID:
22716245
19.

MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma.

Liu S, Kumar SM, Lu H, Liu A, Yang R, Pushparajan A, Guo W, Xu X.

J Pathol. 2012 Jan;226(1):61-72. doi: 10.1002/path.2964. Epub 2011 Aug 24.

20.

The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms.

Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP, Peschle C, Carè A.

Cancer Res. 2008 Apr 15;68(8):2745-54. doi: 10.1158/0008-5472.CAN-07-2538.

Supplemental Content

Support Center